Castle Biosciences (CSTL) Operating Leases (2021 - 2026)

Castle Biosciences has disclosed Operating Leases across 6 years of filings, most recently posting $25.1 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $25.1 million, up 78.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.1 million (up 78.77% YoY), and the FY2025 annual result was $25.2 million, up 75.79% from the prior year.
• Operating Leases came in at $25.1 million for Q1 2026 at Castle Biosciences, roughly flat from $25.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $25.4 million in Q2 2025 to a low of $6.5 million in Q2 2022.
• The 5-year median for Operating Leases is $13.9 million (2024), against an average of $15.3 million.
• Across the five-year window, Operating Leases jumped 91.77% in 2023 and rose 1.21% in 2024, its largest moves.
• Castle Biosciences' Operating Leases stood at $11.5 million in 2022, then rose by 22.89% to $14.2 million in 2023, then grew by 1.21% to $14.3 million in 2024, then jumped by 75.79% to $25.2 million in 2025, then decreased by 0.4% to $25.1 million in 2026.
• The last three Operating Leases figures came in at $25.1 million (Q1 2026), $25.2 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.